Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study.

MLA

Kandane-Rathnayake, Rangi, et al. “Lupus Low Disease Activity State and Remission and Risk of Mortality in Patients with Systemic Lupus Erythematosus: A Prospective, Multinational, Longitudinal Cohort Study.” The Lancet. Rheumatology, vol. 4, no. 12, Dec. 2022, pp. e822–30. EBSCOhost, https://doi.org/10.1016/S2665-9913(22)00304-6.

APA

Kandane-Rathnayake, R., Golder, V., Louthrenoo, W., Chen, Y.-H., Cho, J., Lateef, A., Hamijoyo, L., Luo, S.-F., Wu, Y.-J. J., Navarra, S. V., Zamora, L., Li, Z., Sockalingam, S., Katsumata, Y., Harigai, M., Hao, Y., Zhang, Z., Basnayake, B. M. D. B., Chan, M., … Morand, E. F. (2022). Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study. The Lancet. Rheumatology, 4(12), e822–e830. https://doi.org/10.1016/S2665-9913(22)00304-6

Chicago

Kandane-Rathnayake, Rangi, Vera Golder, Worawit Louthrenoo, Yi-Hsing Chen, Jiacai Cho, Aisha Lateef, Laniyati Hamijoyo, et al. 2022. “Lupus Low Disease Activity State and Remission and Risk of Mortality in Patients with Systemic Lupus Erythematosus: A Prospective, Multinational, Longitudinal Cohort Study.” The Lancet. Rheumatology 4 (12): e822–30. doi:10.1016/S2665-9913(22)00304-6.